News

7 Penny Stocks With Low Floats and High Short Interest

  • There are many ways to approach penny stocks, but one that has gained popularity in recent years focuses on stocks in this category that are prime candidates for a “short squeeze.” A typical short squeeze candidate has a high level of short interest, or percentage of outstanding float sold short.
    11/24/2023

ProKidney Corp. (PROK) Q3 2023 Earnings Call Transcript

  • ProKidney Corp. (NASDAQ:PROK ) Q3 2023 Results Conference Call November 14, 2023 8:00 AM ET Company Participants Dr. Glenn Schulman - SVP of IR Pablo Legorreta - Chairman of Board Dr. Tim Bertram - Co-Founder and Member of Scientific Advisory Board Dr. Bruce Culleton - Chief Executive Officer Conference Call Participants Yigal Nochomovitz - Citi Justin Zelin - BTIG Jonathan Miller - Evercore Jason Gerberry - Bank of America Operator Good morning, ladies and gentlemen, and welcome to the ProKidney Corporate Update Conference Call. At this time, all lines are in a listen-only mode.
    11/16/2023
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

ProKidney Corp. (PROK) can hold. Click on Rating Page for detail.

The price of ProKidney Corp. (PROK) is 1.685 and it was updated on 2023-12-02 07:00:42.

Currently ProKidney Corp. (PROK) is in undervalued.

News
    
News

After Plunging -37.39% in 4 Weeks, Here's Why the Trend Might Reverse for ProKidney Corp. (PROK)

  • The heavy selling pressure might have exhausted for ProKidney Corp. (PROK) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
    Thu, Nov. 16, 2023

ProKidney Corp. (PROK) Loses -54.93% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

  • ProKidney Corp. (PROK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
    Tue, Oct. 17, 2023

Is Chamath Palihapitiya Giving Up on ProKidney (PROK) Stock?

  • Shares of ProKidney (NASDAQ: PROK ) are in the green today, despite recent sales from special purpose acquisition company (SPAC) sponsor Chamath Palihapitiya. Back in July of 2022, ProKidney agreed to merge with Social Capital Suvretta Holdings Corp III in a business combination valued at $2.64 billion.
    Mon, Oct. 16, 2023

Why Shares of ProKidney Were Dropping Thursday

  • ProKidney focuses on therapies to treat chronic kidney disease (CKD). One of its top shareholders sold roughly $1.23 million worth of company stock.
    Thu, Oct. 12, 2023

ProKidney to Participate in Fireside Chat at the Morgan Stanley Global Healthcare Conference

  • WINSTON-SALEM, N.C., Sept. 05, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on preserving kidney function in patients suffering from chronic kidney disease (CKD), today announced that Dr. Tim Bertram, Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference, being held in New York, NY from September 11 – 14, 2023.
    Tue, Sep. 05, 2023
Transcripts
Transcipts Data

ProKidney Corp. (PROK) on Q3 2023 Results - Earnings Call Transcript

  • SA Transcripts
  • Thu, Nov. 16, 2023
SEC Filings
SEC Filings

ProKidney Corp. (PROK) - EFFECT

  • SEC Filings
  • 12/01/2023

ProKidney Corp. (PROK) - 8-K - Current report

  • SEC Filings
  • 11/30/2023

ProKidney Corp. (PROK) - S-3

  • SEC Filings
  • 11/22/2023

ProKidney Corp. (PROK) - 4

  • SEC Filings
  • 11/21/2023

ProKidney Corp. (PROK) - SC 13D/A

  • SEC Filings
  • 11/20/2023

ProKidney Corp. (PROK) - 8-K - Current report

  • SEC Filings
  • 11/20/2023

ProKidney Corp. (PROK) - 4

  • SEC Filings
  • 11/17/2023

ProKidney Corp. (PROK) - 8-K - Current report

  • SEC Filings
  • 11/14/2023

ProKidney Corp. (PROK) - 4

  • SEC Filings
  • 11/14/2023

ProKidney Corp. (PROK) - 8-K - Current report

  • SEC Filings
  • 11/13/2023

ProKidney Corp. (PROK) - 4

  • SEC Filings
  • 11/08/2023

ProKidney Corp. (PROK) - SC 13D/A

  • SEC Filings
  • 11/06/2023

ProKidney Corp. (PROK) - 4

  • SEC Filings
  • 11/03/2023

ProKidney Corp. (PROK) - SC 13D

  • SEC Filings
  • 11/02/2023

ProKidney Corp. (PROK) - 4

  • SEC Filings
  • 11/01/2023

ProKidney Corp. (PROK) - 4

  • SEC Filings
  • 10/31/2023

ProKidney Corp. (PROK) - SC 13D/A

  • SEC Filings
  • 10/27/2023

ProKidney Corp. (PROK) - 4

  • SEC Filings
  • 10/26/2023

ProKidney Corp. (PROK) - 4

  • SEC Filings
  • 10/23/2023

ProKidney Corp. (PROK) - SC 13D/A

  • SEC Filings
  • 10/19/2023

ProKidney Corp. (PROK) - 4

  • SEC Filings
  • 10/18/2023

ProKidney Corp. (PROK) - 4

  • SEC Filings
  • 10/13/2023

ProKidney Corp. (PROK) - 4

  • SEC Filings
  • 10/10/2023

ProKidney Corp. (PROK) - SC 13D/A

  • SEC Filings
  • 09/21/2023

ProKidney Corp. (PROK) - 4

  • SEC Filings
  • 09/21/2023

ProKidney Corp. (PROK) - 8-K - Current report

  • SEC Filings
  • 09/11/2023

ProKidney Corp. (PROK) - 4

  • SEC Filings
  • 08/29/2023

ProKidney Corp. (PROK) - 424B3

  • SEC Filings
  • 08/23/2023

ProKidney Corp. (PROK) - EFFECT

  • SEC Filings
  • 08/22/2023

ProKidney Corp. (PROK) - POS AM

  • SEC Filings
  • 08/18/2023

ProKidney Corp. (PROK) - 424B3

  • SEC Filings
  • 08/11/2023

ProKidney Corp. (PROK) - 8-K - Current report

  • SEC Filings
  • 08/10/2023

ProKidney Corp. (PROK) - 10-Q - Quarterly Report

  • SEC Filings
  • 08/10/2023

ProKidney Corp. (PROK) - 4

  • SEC Filings
  • 08/03/2023

ProKidney Corp. (PROK) - 424B3

  • SEC Filings
  • 07/25/2023

ProKidney Corp. (PROK) - 3

  • SEC Filings
  • 07/25/2023

ProKidney Corp. (PROK) - 8-K - Current report

  • SEC Filings
  • 07/18/2023

ProKidney Corp. (PROK) - 4

  • SEC Filings
  • 07/13/2023

ProKidney Corp. (PROK) - 424B3

  • SEC Filings
  • 07/06/2023

ProKidney Corp. (PROK) - 4

  • SEC Filings
  • 07/03/2023

ProKidney Corp. (PROK) - 8-K - Current report

  • SEC Filings
  • 06/30/2023

ProKidney Corp. (PROK) - 424B3

  • SEC Filings
  • 06/23/2023

ProKidney Corp. (PROK) - 8-K - Current report

  • SEC Filings
  • 06/16/2023

ProKidney Corp. (PROK) - DEF 14A

  • SEC Filings
  • 05/26/2023

ProKidney Corp. (PROK) - ARS

  • SEC Filings
  • 05/26/2023

ProKidney Corp. (PROK) - 424B3

  • SEC Filings
  • 05/26/2023

ProKidney Corp. (PROK) - 8-K - Current report

  • SEC Filings
  • 05/11/2023

ProKidney Corp. (PROK) - 10-Q - Quarterly Report

  • SEC Filings
  • 05/11/2023

ProKidney Corp. (PROK) - 10-K/A - Current report

  • SEC Filings
  • 04/27/2023

ProKidney Corp. (PROK) - EFFECT

  • SEC Filings
  • 04/21/2023

ProKidney Corp. (PROK) - 424B3

  • SEC Filings
  • 04/21/2023

ProKidney Corp. (PROK) - POS AM

  • SEC Filings
  • 04/17/2023

ProKidney Corp. (PROK) - 4

  • SEC Filings
  • 04/04/2023

ProKidney Corp. (PROK) - S-8

  • SEC Filings
  • 03/29/2023

ProKidney Corp. (PROK) - 8-K - Current report

  • SEC Filings
  • 03/28/2023

ProKidney Corp. (PROK) - 10-K - Current report

  • SEC Filings
  • 03/28/2023

ProKidney Corp. (PROK) - 424B3

  • SEC Filings
  • 03/07/2023

ProKidney Corp. (PROK) - 8-K - Current report

  • SEC Filings
  • 03/06/2023

ProKidney Corp. (PROK) - SC 13G/A

  • SEC Filings
  • 02/14/2023

ProKidney Corp. (PROK) - SC 13G/A

  • SEC Filings
  • 02/13/2023

ProKidney Corp. (PROK) - SC 13G/A

  • SEC Filings
  • 02/10/2023

ProKidney Corp. (PROK) - SC 13G/A

  • SEC Filings
  • 02/09/2023

ProKidney Corp. (PROK) - 8-K - Current report

  • SEC Filings
  • 02/06/2023

ProKidney Corp. (PROK) - 424B3

  • SEC Filings
  • 02/06/2023

ProKidney Corp. (PROK) - 424B3

  • SEC Filings
  • 01/20/2023

ProKidney Corp. (PROK) - 8-K - Current report

  • SEC Filings
  • 01/19/2023

ProKidney Corp. (PROK) - 4

  • SEC Filings
  • 01/18/2023

ProKidney Corp. (PROK) - 424B3

  • SEC Filings
  • 01/11/2023

ProKidney Corp. (PROK) - 8-K - Current report

  • SEC Filings
  • 01/10/2023

ProKidney Corp. (PROK) - 4

  • SEC Filings
  • 01/06/2023

ProKidney Corp. (PROK) - 3

  • SEC Filings
  • 01/06/2023

ProKidney Corp. (PROK) - 424B3

  • SEC Filings
  • 12/08/2022

ProKidney Corp. (PROK) - 8-K - Current report

  • SEC Filings
  • 12/06/2022

ProKidney Corp. (PROK) - 424B3

  • SEC Filings
  • 11/29/2022

ProKidney Corp. (PROK) - 8-K - Current report

  • SEC Filings
  • 11/14/2022

ProKidney Corp. (PROK) - 10-Q - Quarterly Report

  • SEC Filings
  • 11/14/2022

ProKidney Corp. (PROK) - 4

  • SEC Filings
  • 10/24/2022

ProKidney Corp. (PROK) - 4

  • SEC Filings
  • 09/22/2022

ProKidney Corp. (PROK) - S-8

  • SEC Filings
  • 09/14/2022

ProKidney Corp. (PROK) - SC 13G

  • SEC Filings
  • 09/12/2022

ProKidney Corp. (PROK) - 424B3

  • SEC Filings
  • 09/09/2022

ProKidney Corp. (PROK) - EFFECT

  • SEC Filings
  • 09/08/2022

ProKidney Corp. (PROK) - 8-K - Current report

  • SEC Filings
  • 09/08/2022

ProKidney Corp. (PROK) - 4

  • SEC Filings
  • 09/08/2022

ProKidney Corp. (PROK) - CORRESP

  • SEC Filings
  • 09/06/2022

ProKidney Corp. (PROK) - 4

  • SEC Filings
  • 09/01/2022

ProKidney Corp. (PROK) - S-1/A

  • SEC Filings
  • 08/26/2022

ProKidney Corp. (PROK) - CORRESP

  • SEC Filings
  • 08/26/2022

ProKidney Corp. (PROK) - UPLOAD

  • SEC Filings
  • 08/15/2022

ProKidney Corp. (PROK) - 8-K/A - Current report

  • SEC Filings
  • 08/12/2022

ProKidney Corp. (PROK) - 8-K - Current report

  • SEC Filings
  • 08/12/2022

ProKidney Corp. (PROK) - 10-Q - Quarterly Report

  • SEC Filings
  • 08/12/2022

ProKidney Corp. (PROK) - S-1

  • SEC Filings
  • 08/09/2022

ProKidney Corp. (PROK) - SC 13G

  • SEC Filings
  • 07/22/2022

ProKidney Corp. (PROK) - SC 13D

  • SEC Filings
  • 07/22/2022

ProKidney Corp. (PROK) - SC 13G/A

  • SEC Filings
  • 07/21/2022

ProKidney Corp. (PROK) - 3

  • SEC Filings
  • 07/21/2022

ProKidney Corp. (PROK) - SC 13D

  • SEC Filings
  • 07/20/2022

ProKidney Corp. (PROK) - 4/A

  • SEC Filings
  • 07/20/2022

ProKidney Corp. (PROK) - 3

  • SEC Filings
  • 07/20/2022

ProKidney Corp. (PROK) - 8-K - Current report

  • SEC Filings
  • 07/15/2022

ProKidney Corp. (PROK) - 4

  • SEC Filings
  • 07/13/2022

ProKidney Corp. (PROK) - 3

  • SEC Filings
  • 07/13/2022

ProKidney Corp. (PROK) - 8-K - Current report

  • SEC Filings
  • 07/12/2022

ProKidney Corp. (PROK) - DEFA14A

  • SEC Filings
  • 07/11/2022

ProKidney Corp. (PROK) - 8-K - Current report

  • SEC Filings
  • 07/11/2022

ProKidney Corp. (PROK) - DEFA14A

  • SEC Filings
  • 07/06/2022

ProKidney Corp. (PROK) - 8-K - Current report

  • SEC Filings
  • 07/06/2022

ProKidney Corp. (PROK) - DEFA14A

  • SEC Filings
  • 06/23/2022

ProKidney Corp. (PROK) - DEFA14A

  • SEC Filings
  • 06/15/2022

ProKidney Corp. (PROK) - DEFM14A

  • SEC Filings
  • 06/10/2022

ProKidney Corp. (PROK) - 8-K/A - Current report

  • SEC Filings
  • 06/10/2022

ProKidney Corp. (PROK) - DEFA14A

  • SEC Filings
  • 06/08/2022

ProKidney Corp. (PROK) - DEFA14A

  • SEC Filings
  • 06/07/2022

ProKidney Corp. (PROK) - DEFA14A

  • SEC Filings
  • 05/26/2022

ProKidney Corp. (PROK) - DEFA14A

  • SEC Filings
  • 05/20/2022

ProKidney Corp. (PROK) - UPLOAD

  • SEC Filings
  • 05/17/2022

ProKidney Corp. (PROK) - 10-Q - Quarterly Report

  • SEC Filings
  • 05/16/2022

ProKidney Corp. (PROK) - DEFA14A

  • SEC Filings
  • 05/11/2022

ProKidney Corp. (PROK) - PRER14A

  • SEC Filings
  • 05/06/2022

ProKidney Corp. (PROK) - CORRESP

  • SEC Filings
  • 05/06/2022

ProKidney Corp. (PROK) - DEFA14A

  • SEC Filings
  • 05/03/2022

ProKidney Corp. (PROK) - DEFA14A

  • SEC Filings
  • 04/28/2022

ProKidney Corp. (PROK) - 8-K - Current report

  • SEC Filings
  • 04/28/2022

ProKidney Corp. (PROK) - UPLOAD

  • SEC Filings
  • 04/25/2022

ProKidney Corp. (PROK) - 8-K - Current report

  • SEC Filings
  • 04/22/2022

ProKidney Corp. (PROK) - DEFA14A

  • SEC Filings
  • 04/18/2022

ProKidney Corp. (PROK) - DEFA14A

  • SEC Filings
  • 04/12/2022

ProKidney Corp. (PROK) - PRER14A

  • SEC Filings
  • 04/11/2022

ProKidney Corp. (PROK) - CORRESP

  • SEC Filings
  • 04/11/2022

ProKidney Corp. (PROK) - DEFA14A

  • SEC Filings
  • 03/28/2022

ProKidney Corp. (PROK) - 10-K - Current report

  • SEC Filings
  • 03/24/2022

ProKidney Corp. (PROK) - UPLOAD

  • SEC Filings
  • 03/17/2022

ProKidney Corp. (PROK) - DEFA14A

  • SEC Filings
  • 03/01/2022

ProKidney Corp. (PROK) - PREM14A

  • SEC Filings
  • 02/14/2022

ProKidney Corp. (PROK) - SC 13G

  • SEC Filings
  • 02/09/2022

ProKidney Corp. (PROK) - DEFA14A

  • SEC Filings
  • 01/27/2022

ProKidney Corp. (PROK) - SC 13G/A

  • SEC Filings
  • 01/25/2022

ProKidney Corp. (PROK) - DEFA14A

  • SEC Filings
  • 01/21/2022

ProKidney Corp. (PROK) - 8-K/A - Current report

  • SEC Filings
  • 01/21/2022

ProKidney Corp. (PROK) - DEFA14A

  • SEC Filings
  • 01/19/2022

ProKidney Corp. (PROK) - DEFA14A

  • SEC Filings
  • 01/18/2022

ProKidney Corp. (PROK) - 8-K - Current report

  • SEC Filings
  • 01/18/2022

ProKidney Corp. (PROK) - SC 13G

  • SEC Filings
  • 12/29/2021

ProKidney Corp. (PROK) - 8-K - Current report

  • SEC Filings
  • 11/16/2021

ProKidney Corp. (PROK) - 10-Q - Quarterly Report

  • SEC Filings
  • 11/15/2021

ProKidney Corp. (PROK) - 8-K - Current report

  • SEC Filings
  • 09/24/2021

ProKidney Corp. (PROK) - 3

  • SEC Filings
  • 09/24/2021

ProKidney Corp. (PROK) - 4

  • SEC Filings
  • 08/16/2021

ProKidney Corp. (PROK) - 10-Q - Quarterly Report

  • SEC Filings
  • 08/16/2021

ProKidney Corp. (PROK) - SC 13G

  • SEC Filings
  • 07/12/2021

ProKidney Corp. (PROK) - 8-K - Current report

  • SEC Filings
  • 07/09/2021

ProKidney Corp. (PROK) - SC 13G

  • SEC Filings
  • 07/08/2021

ProKidney Corp. (PROK) - 4

  • SEC Filings
  • 07/07/2021

ProKidney Corp. (PROK) - 8-K - Current report

  • SEC Filings
  • 07/02/2021

ProKidney Corp. (PROK) - 424B4

  • SEC Filings
  • 07/01/2021

ProKidney Corp. (PROK) - S-1MEF

  • SEC Filings
  • 06/30/2021

ProKidney Corp. (PROK) - EFFECT

  • SEC Filings
  • 06/29/2021

ProKidney Corp. (PROK) - CERT

  • SEC Filings
  • 06/29/2021

ProKidney Corp. (PROK) - 8-A12B

  • SEC Filings
  • 06/29/2021

ProKidney Corp. (PROK) - 3

  • SEC Filings
  • 06/29/2021

ProKidney Corp. (PROK) - S-1/A

  • SEC Filings
  • 06/25/2021

ProKidney Corp. (PROK) - CORRESP

  • SEC Filings
  • 06/25/2021

ProKidney Corp. (PROK) - UPLOAD

  • SEC Filings
  • 06/15/2021

ProKidney Corp. (PROK) - S-1/A

  • SEC Filings
  • 06/09/2021

ProKidney Corp. (PROK) - S-1

  • SEC Filings
  • 06/02/2021

ProKidney Corp. (PROK) - DRS

  • SEC Filings
  • 04/21/2021
Press Releases
StockPrice Release

Prokidney appoints nikhil pereira-kamath, mba, as chief business officer

  • 11/30/2023

Prokidney to participate in a fireside chat at the upcoming evercore isi 6th annual healthconx conference

  • 11/21/2023

Prokidney reports third quarter financial results

  • 11/14/2023

Prokidney announces positive interim data from rmcl-002 phase 2 clinical trial of renal autologous cell therapy (react®) for diabetic ckd and provides corporate updates

  • 11/13/2023

Prokidney announces four abstracts selected for presentation at the american society of nephrology's kidney week 2023

  • 10/30/2023

Prokidney to participate in fireside chat at the morgan stanley global healthcare conference

  • 09/05/2023

Prokidney reports second quarter financial results and recent corporate highlights

  • 08/10/2023

Prokidney announces closing of purchase of manufacturing facility in greensboro, nc

  • 07/18/2023

Prokidney appoints bruce culleton, md, as executive vice president, clinical development and commercialization

  • 07/15/2023

Prokidney announces purchase of manufacturing facility in greensboro, nc

  • 06/13/2023

Prokidney to participate in fireside chat at the jefferies healthcare conference

  • 06/01/2023

Prokidney to present at the bofa securities health care conference 2023

  • 05/04/2023

Prokidney reports fourth quarter financial results and recent corporate highlights

  • 03/28/2023

Prokidney to participate in td cowen's 43rd annual health care conference

  • 03/03/2023

Prokidney to present at the j.p. morgan 41st annual healthcare conference

  • 12/22/2022

Prokidney reports third quarter 2022 financial results and recent corporate highlights

  • 11/14/2022

Prokidney to participate in upcoming investor conferences

  • 11/11/2022

Prokidney receives allowance from the uk medicines and healthcare products regulatory agency (mhra) for proact 1 (regen-006) and ema scientific advice on phase 3 protocols of react for diabetic chronic kidney disease

  • 11/03/2022

Prokidney announces multiple abstracts selected for presentation at the american society of nephrology's kidney week 2022

  • 10/14/2022

Prokidney to present at the jefferies cell and genetic medicine summit

  • 09/23/2022

Prokidney to present at the morgan stanley 20th annual global healthcare conference

  • 09/08/2022

Prokidney appoints glenn schulman, pharmd, mph, as senior vice president of investor relations

  • 08/31/2022

Prokidney corp. reports second quarter 2022 financial results and provides business update

  • 08/11/2022

Prokidney strengthens board of directors with appointments of dr. john m. maraganore and jennifer fox

  • 08/11/2022

Prokidney appoints kerry cooper, m.d., as senior vice president of medical affairs

  • 07/20/2022

Social capital suvretta holdings corp. iii announces reconvened extraordinary general meeting of shareholders

  • 07/08/2022

Prokidney corroborates the mechanism of action of react™ with cell marker analysis in patients with diabetic chronic kidney disease

  • 06/23/2022

Prokidney announces manufacturing efficiency initiatives and supply chain streamlining expected to reduce react™ manufacturing costs

  • 06/15/2022

Observed safety profile supports bilateral dosing of prokidney's react™ – 007 update

  • 06/07/2022

Prokidney to present at upcoming investor conferences

  • 05/20/2022

Prokidney highlights key registrational program elements supporting advancement of react®

  • 05/03/2022

Prokidney appoints libbie parker mckenzie, md, fasn as chief medical officer

  • 04/28/2022

Prokidney and social capital suvretta holdings corp. iii (“scs”) to host analyst and investor day on april 28, 2022

  • 04/18/2022

Prokidney confirms phase 3 program for autologous kidney cell therapy react®

  • 04/12/2022

Prokidney appoints todd c. girolamo as general counsel

  • 03/28/2022

Prokidney to present react® at 4th annual ckd summit

  • 03/01/2022

Shareholder alert: rigrodsky law, p.a. announces investigation of social capital suvretta holdings corp. iii merger

  • 02/04/2022

Prokidney announces online publication of trial design for phase ii multicenter clinical trial of react® autologous cell therapy for treatment of chronic kidney disease

  • 01/27/2022

Revolutionary chronic kidney disease therapeutics company prokidney to become publicly traded via business combination with social capital suvretta holdings corp. iii

  • 01/18/2022

Schneider electric announces 2021 list of master-level ecoxpert™ partners in critical power & substation automation solutions

  • 02/26/2021
More Headlines
News

Short squeeze alert for September 4th: Two stocks with potential to skyrocket

  • A short squeeze is when traders who heavily short a stock start to cover their short positions by buying back the stock. This increases demand for the stock, and it pushes the price higher, forcing other short sellers to buy back.
  • 09/04/2023

3 Biotech Stocks Due for a Massive Short Squeeze

  • Here's a look at 3 biotech short squeeze candidates. For investors looking for short-term gains, technical analysis provides key insights on potential entry and exit points.
  • 08/31/2023

ProKidney to Present at the BofA Securities Health Care Conference 2023

  • WINSTON-SALEM, N.C., May 04, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that Dr. Tim Bertram, Chief Executive Officer, will present at the BofA Securities Health Care Conference 2023 in Las Vegas, NV on Tuesday, May 9, 2023, at 4:20 PM PDT (7:20 PM EDT).
  • 05/04/2023

ProKidney: Too Many Billionaires, Too Little Data

  • ProKidney Corp. has a noble goal - ending kidney dysfunction using cell therapy. It has produced some interesting data from a phase 2 trial.
  • 04/12/2023

ProKidney's stock jumps 29%

  • Shares of ProKidney Corp. PROK, +9.57% rallied about 29% in premarket trading on Wednesday, the day after the company said preliminary data from a Phase 2 study found that the company's investigational renal autologous cell therapy treatment can delay the need for dialysis in some patients with chronic kidney disease. The study was published Jan. 4 in the journal Blood Purification; the company issued a news release about the study on Tuesday.
  • 01/11/2023

ProKidney to Present at the J.P. Morgan 41st Annual Healthcare Conference

  • WINSTON-SALEM, N.C., Dec. 22, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that Dr. Tim Bertram, Chief Executive Officer, will present at the J.P. Morgan 41st Annual Healthcare Conference in San Francisco on Wednesday, January 11th, 2023, at 3:45 PM PT.
  • 12/22/2022

ProKidney to Participate in Upcoming Investor Conferences

  • WINSTON-SALEM, N.C., Nov. 11, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that Dr. Tim Bertram, Chief Executive Officer, will participate in the following upcoming investor conferences:
  • 11/11/2022

ProKidney to Present at the Jefferies Cell and Genetic Medicine Summit

  • WINSTON-SALEM, N.C., Sept. 23, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that Dr. Tim Bertram, Chief Executive Officer of ProKidney, will present a corporate overview at the Jefferies Cell and Genetic Medicine Summit at 1:30 p.m. ET on Thursday, September 29, 2022, in New York, NY.
  • 09/23/2022

ProKidney to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

  • WINSTON-SALEM, N.C., Sept. 08, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that Dr. Tim Bertram, Chief Executive Officer of ProKidney, will participate in a fireside chat on Wednesday, September 14, 2022, at the Morgan Stanley 20 th Annual Global Healthcare Conference, in New York, NY. During the fireside chat, ProKidney plans to discuss its commercialization strategies and potential line extensions to expand market access, approaches to drive down cost of goods, and scaling of manufacturing to meet future market demand.
  • 09/08/2022

ProKidney to present at upcoming investor conferences

  • WINSTON-SALEM, N.C., May 20, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on the treatment of chronic kidney disease (CKD) and the prevention of both end-stage renal disease (ESRD) and the need for dialysis, today announced that Tim Bertram, PhD, Chief Executive Officer, will present at the following investor conferences:
  • 05/20/2022

ProKidney to Present REACT® at 4th Annual CKD Summit

  • WINSTON-SALEM, N.C., March 01, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease (CKD) and prevention of end-stage renal disease (ESRD) and need for dialysis, today announced that Joseph Stavas, MD, MPH, Senior Vice President of Clinical Development, will present data on the Company's lead product candiate, Renal Autologous Cell Therapy (REACT®) at the 4th Annual CKD Summit, being held March 1-3, 2022 in Boston, MA.
  • 03/01/2022

ProKidney To Become Publicly Traded Through Combination With Social Capital Suvretta Holdings Corp. III (DNAC)

  • ProKidney entered into a definitive agreement to become a publicly-traded company via a business combination with Social Capital Suvretta Holdings Corp. III (Nasdaq: DNAC). These are the details.
  • 01/18/2022

ProKidney Turns To Palihapitiya-Backed SPAC To Go Public In $2.6B Deal

  • ProKidney LP agreed to become a publicly-traded company via a business combination with Chamath Palihapitiya-backed special purpose acquisition company Social Capital Suvretta Holdings Corp III  (NASDAQ: DNAC) in a deal valuing the combined entity at $2.64 billion. ProKidney first made waves in 2019, when it disclosed the $62 million acquisition of inRegen and raised $75 million to fund the deal and another takeover.
  • 01/18/2022

ProKidney set to go public after SPAC merger that values combined company at $2.6 billion

  • ProKidney LP, a cellular therapeutics company focused on kidney disease, announced an agreement to merge with special purpose acquisition company (SPAC) Social Capital Suvretta Holdings Corp. III DNAC, +0.19% in a deal that values the combined company at $2.64 billion. The deal, which will take ProKidney public, is expected to provide $825 million in cash proceeds.
  • 01/18/2022

2 Chamath Palihapitiya SPAC Deals Rumored: Will He Land The Year's First Deal Once Again?

  • The 2022 year has started quietly for SPACs, with no deals announced in the first five trading days of the year. Although two new SPAC rumors have popped up since the market closed on Friday and both involve a well-known name in the SPAC space.
  • 01/09/2022
Unlock
PROK Ratings Summary
PROK Quant Ranking